Korean J Urol.  1999 May;40(5):551-556.

Urinary NMP(nuclear matrix protein)22 in Screening and Post-treatment Follow-up of Bladder Cancer

Affiliations
  • 1Department of Urology, Korea University College of Medicine, Seoul, Korea.

Abstract

PURPOSE: Successful treatment of bladder cancer greatly depend upon the regular surveillance for early detection of persistent or recurrent cancer. We assessed the efficacy of urinary NMP22 test in screening and post-trearment follow-up for bladder cancer.
MATERIALS AND METHODS
Urinary NMP22 test kit, which is based on an enzyme-linked immunosorbent assays, were used to measure the values of urinary NMP22 in 30 patients of transitional cell carcinoma of the bladder, 32 healthy volunteers, 12 patients of urinary tract infection and 13 patients of other urinary malignancy.
RESULTS
Median values of urinary NMP22 in patients with bladder cancer were significantly greater than in healthy volunteers(p<0.05). With a cutoff value of 15units/ml, urinary NMP22 test had a 90.0% of sensitivity and a 90.6% of specificity in predicting bladder cancer. There was significant postoperative decrease of urinary NMP22 values in all patients with bladder cancer(p<0.05).
CONCLUSIONS
These results suggest that urinary NMP22 test is useful for screening and postoperative surveillance of patients with transitional cell carcinoma of urinary bladder. Further comparative studies of urinary NMP22 test with the results of postoperative cystoscopy or cold cup biopsies are requested to enhance the practical utility of urinary NMP22 test.

Keyword

Bladder cancer; NMP22

MeSH Terms

Biopsy
Carcinoma, Transitional Cell
Cystoscopy
Enzyme-Linked Immunosorbent Assay
Follow-Up Studies*
Healthy Volunteers
Humans
Mass Screening*
Sensitivity and Specificity
Urinary Bladder Neoplasms*
Urinary Bladder*
Urinary Tract Infections
Full Text Links
  • KJU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr